GenSpera has filed a 10-Q – Quarterly report [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission (Filing, 10-Q, GenSpera, 2017, NOV 20, 2017, View Source [SID1234522171]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On November 20, 2017 Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, reported that new preclinical data for its novel covalent EGFR inhibitor were presented at the Society for Neuro-Oncology 22nd Annual Meeting, November 16-19, in San Francisco (Press release, Trillium Therapeutics, NOV 20, 2017, View Source [SID1234522151]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Presentation: TTI-2341: A novel, orally bioavailable, brain-penetrant, covalent epidermal growth factor receptor (EGFR) inhibitor for treatment of glioblastoma multiforme (GBM) and brain metastases of non-small cell lung cancer (NSCLC).

This poster presentation highlighted preclinical data for TTI-2341, a novel covalent EGFR inhibitor. TTI-2341 had potent activity against a broad range of EGFR variants, including disease-relevant mutants T790M and C797S. TTI-2341 was shown to penetrate the blood brain barrier and demonstrated superior ADME properties and oral bioavailability relative to benchmark drugs afatinib and osimertinib. Notably, TTI-2341 achieved greater than 20-fold higher free drug brain exposure compared to osimertinib and was well tolerated at levels expected to be efficacious.

"Aberrant EGFR activity is clearly implicated in CNS tumors, particularly glioblastoma multiforme and brain metastases of non-small cell lung cancer," said Trillium CEO Dr. Niclas Stiernholm. "Currently available EGFR inhibitors have demonstrated limited efficacy due to poor penetration of the blood brain barrier and low activity against resistance-associated EGFR mutations. Our emerging preclinical data suggests that TTI-2341 can overcome these limitations."

Oncbiomune has filed a 10-Q – Quarterly report [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission (Filing, 10-Q, OncBioMune Pharmaceuticals, 2017, NOV 20, 2017, View Source [SID1234522178]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On November 20, 2017 NewLink Genetics Corporation (NASDAQ:NLNK) reported the presentation of data from a Phase 1 study of indoximod, in combination with radiation, for children with progressive brain tumors (Press release, NewLink Genetics, NOV 20, 2017, View Source [SID1234522177]). These data were presented at the Society for NeuroOncology, 22nd Annual Meeting, in San Francisco, CA, on November 19, 2017, by Theodore S. Johnson, M.D., Ph.D., Associate Professor of Pediatrics at Augusta University.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation entitled, "Radio-chemo-immunotherapy using the IDO-inhibitor indoximod for children with progressive brain tumors in the phase 1 setting" showed the combination of indoximod plus radiation was well-tolerated.

"We are very pleased with early study data combining salvage radiation therapy with indoximod. This combination seems to be well-tolerated in children with recurrent brain tumors, despite their previous treatment with high-dose radiation plans," said Theodore S. Johnson, M.D., Ph.D., Associate Professor of Pediatrics at Augusta University. "We applaud NewLink Genetics for providing access to indoximod for the children enrolling in this first-in-children study."

A link to the presentation slides can be accessed through the NewLink Genetics website at www.NewLinkGenetics.com in the "Investors & Media" section under "Events & Presentations." A second presentation, complete with scan images, given by Dr. Johnson at the Texas Children’s Neuro-oncology Conference on November 10, 2017 can be found listed in the same location on NewLink’s website. Additional information for this study, NLG2105 for pediatric patients with refractory malignant brain tumors, may be found here.

On November 20, 2017 Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or "the Company") reported that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the 29th Annual Piper Jaffray Healthcare Conference as follows (Press release, Eagle Pharmaceuticals, NOV 20, 2017, View Source [SID1234522176]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Date: Wednesday, November 29, 2017
Time: 11:30 a.m. Eastern Standard Time
Location: Lotte New York Palace, New York
Webcast:

View Source;tp_key=fc44350be5

The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Company’s website at www.eagleus.com, under the Investors Section.